283 related articles for article (PubMed ID: 33542481)
21. Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT).
Maffini E; Labopin M; Beelen DW; Kroeger N; Arat M; Wilson KMO; Bay JO; Ganser A; Martin H; Passweg J; Kottaridis PD; Yakoub-Agha I; Porras RP; Wagner EM; Esteve J; Lanza F; Nagler A; Mohty M
Bone Marrow Transplant; 2022 Oct; 57(10):1556-1563. PubMed ID: 35835997
[TBL] [Abstract][Full Text] [Related]
22. The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial.
Marks DI; Moorman AV; Chilton L; Paietta E; Enshaie A; DeWald G; Harrison CJ; Fielding AK; Foroni L; Goldstone AH; Litzow MR; Luger SM; McMillan AK; Racevskis J; Rowe JM; Tallman MS; Wiernik P; Lazarus HM
Haematologica; 2013 Jun; 98(6):945-52. PubMed ID: 23349309
[TBL] [Abstract][Full Text] [Related]
23. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia.
Gökbuget N; Dombret H; Giebel S; Bruggemann M; Doubek M; Foà R; Hoelzer D; Kim C; Martinelli G; Parovichnikova E; Rambaldi A; Ribera JM; Schoonen M; Stieglmaier JM; Zugmaier G; Bassan R
Hematology; 2019 Dec; 24(1):337-348. PubMed ID: 30757960
[TBL] [Abstract][Full Text] [Related]
24. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials.
Eckert C; Parker C; Moorman AV; Irving JA; Kirschner-Schwabe R; Groeneveld-Krentz S; Révész T; Hoogerbrugge P; Hancock J; Sutton R; Henze G; Chen-Santel C; Attarbaschi A; Bourquin JP; Sramkova L; Zimmermann M; Krishnan S; von Stackelberg A; Saha V
Eur J Cancer; 2021 Jul; 151():175-189. PubMed ID: 34010787
[TBL] [Abstract][Full Text] [Related]
25. Clinicians' Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study.
Gidman W; Shah S; Zhang L; McKendrick J; Cong Z; Cohan D; Ottmann O
Adv Ther; 2019 Nov; 36(11):3017-3029. PubMed ID: 31586302
[TBL] [Abstract][Full Text] [Related]
26. Predictive Value of Dynamic Peri-Transplantation MRD Assessed By MFC Either Alone or in Combination with Other Variables for Outcomes of Patients with T-Cell Acute Lymphoblastic Leukemia.
Wang ZD; Wang YW; Xu LP; Zhang XH; Wang Y; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Wang YZ; Liu YR; Liu KY; Huang XJ; Chang YJ
Curr Med Sci; 2021 Jun; 41(3):443-453. PubMed ID: 34185250
[TBL] [Abstract][Full Text] [Related]
27. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
Sutton R; Shaw PJ; Venn NC; Law T; Dissanayake A; Kilo T; Haber M; Norris MD; Fraser C; Alvaro F; Revesz T; Trahair TN; Dalla-Pozza L; Marshall GM; O'Brien TA
Br J Haematol; 2015 Feb; 168(3):395-404. PubMed ID: 25312094
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/
Attarbaschi A; Möricke A; Harrison CJ; Mann G; Baruchel A; De Moerloose B; Conter V; Devidas M; Elitzur S; Escherich G; Hunger SP; Horibe K; Manabe A; Loh ML; Pieters R; Schmiegelow K; Silverman LB; Stary J; Vora A; Pui CH; Schrappe M; Zimmermann M;
J Clin Oncol; 2023 Mar; 41(7):1404-1422. PubMed ID: 36256911
[TBL] [Abstract][Full Text] [Related]
29. The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation.
Nagler A; Dholaria B; Labopin M; Socie G; Huynh A; Itälä-Remes M; Deconinck E; Yakoub-Agha I; Cahn JY; Bourhis JH; Labussière-Wallet H; Chantepie S; Esteve J; Savani B; Mohty M
Leukemia; 2020 Apr; 34(4):1144-1153. PubMed ID: 31728052
[TBL] [Abstract][Full Text] [Related]
30. Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics.
Eckert C; Groeneveld-Krentz S; Kirschner-Schwabe R; Hagedorn N; Chen-Santel C; Bader P; Borkhardt A; Cario G; Escherich G; Panzer-Grümayer R; Astrahantseff K; Eggert A; Sramkova L; Attarbaschi A; Bourquin JP; Peters C; Henze G; von Stackelberg A;
J Clin Oncol; 2019 Dec; 37(36):3493-3506. PubMed ID: 31644328
[TBL] [Abstract][Full Text] [Related]
31. Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML).
Pigneux A; Labopin M; Maertens J; Cordonnier C; Volin L; Socié G; Blaise D; Craddock C; Milpied N; Bacher U; Malard F; Esteve J; Nagler A; Mohty M;
Leukemia; 2015 Dec; 29(12):2375-81. PubMed ID: 26082270
[TBL] [Abstract][Full Text] [Related]
32. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
[TBL] [Abstract][Full Text] [Related]
33. Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission.
Nagler A; Labopin M; Dholaria B; Blaise D; Bondarenko S; Vydra J; Choi G; Rovira M; Reményi P; Meijer E; Bulabois CE; Diez-Martin JL; Yakoub-Agha I; Brissot E; Spyridonidis A; Sanz J; Patel A; Arat M; Bazarbachi A; Bug G; Savani BN; Giebel S; Ciceri F; Mohty M
Br J Haematol; 2023 Jun; 201(6):1169-1178. PubMed ID: 36949658
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
Poiré X; Labopin M; Maertens J; Yakoub-Agha I; Blaise D; Ifrah N; Socié G; Gedde-Dhal T; Schaap N; Cornelissen JJ; Vigouroux S; Sanz J; Michaux L; Esteve J; Mohty M; Nagler A
J Hematol Oncol; 2017 Jan; 10(1):20. PubMed ID: 28100265
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission.
Konuma T; Kondo T; Masuko M; Shimizu H; Shiratori S; Fukuda T; Kato J; Sawa M; Ozawa Y; Ota S; Uchida N; Kanda Y; Kako S; Fujisawa S; Fukushima K; Ichinohe T; Atsuta Y; Yanada M;
Bone Marrow Transplant; 2021 Nov; 56(11):2779-2787. PubMed ID: 34272486
[TBL] [Abstract][Full Text] [Related]
36. Gene expression profiling of adult t(4;11)(q21;q23)-associated acute lymphoblastic leukemia reveals a different signature from pediatric cases.
De Braekeleer E; Douet-Guilbert N; Le Bris MJ; Basinko A; Morel F; De Braekeleer M
Anticancer Res; 2012 Sep; 32(9):3893-9. PubMed ID: 22993334
[TBL] [Abstract][Full Text] [Related]
37. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study.
Vey N; Thomas X; Picard C; Kovascovicz T; Charin C; Cayuela JM; Dombret H; Dastugue N; Huguet F; Bastard C; Stamatoulas A; Giollant M; Tournilhac O; Macintyre E; Buzyn A; Bories D; Kuentz M; Dreyfus F; Delannoy A; Raynaud S; Gratecos N; Bordessoule D; de Botton S; Preudhomme C; Reman O; Troussard X; Pigneux A; Bilhou C; Vernant JP; Boucheix C; Gabert J;
Leukemia; 2006 Dec; 20(12):2155-61. PubMed ID: 17039234
[TBL] [Abstract][Full Text] [Related]
39. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study.
Kim R; Bergugnat H; Pastoret C; Pasquier F; Raffoux E; Larcher L; Passet M; Grardel N; Delabesse E; Kubetzko S; Caye-Eude A; Meyer C; Marschalek R; Lafage-Pochitaloff M; Thiebaut-Bertrand A; Balsat M; Escoffre-Barbe M; Blum S; Baumann M; Banos A; Straetmans N; Gallego-Hernanz MP; Chalandon Y; Graux C; Soulier J; Leguay T; Hunault M; Huguet F; Lhéritier V; Dombret H; Boissel N; Clappier E
Blood; 2023 Nov; 142(21):1806-1817. PubMed ID: 37595275
[TBL] [Abstract][Full Text] [Related]
40. Effect of sustained measurable residue disease negativity and post-remission treatment selection on the prognosis of acute lymphoblastic leukemia in adults.
Yu J; Luo Y; Wang L; Wang T; Ye M; Chen J; Ni X; Chen L; Gao L; Yang J
Cancer Med; 2024 May; 13(10):e7310. PubMed ID: 38785213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
